HMG‐CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors
Open Access
- 4 June 2008
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 123 (5) , 1146-1153
Abstract
Although several studies have reported on the anti‐tumoural properties exerted by 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase (HMG‐CoAR) inhibitors (statins), the in vivo expression of HMG‐CoAR in human cancer has been considerably less investigated. In our study, we examined the immunohistochemical expression of HMG‐CoAR in 511 incident breast cancers within the Malmö Diet and Cancer Study in order to explore its relationship to established clinicopathological and tumour biological parameters. Furthermore, the potential influence of estrogen exposure on HMG‐CoAR expression was assessed by performing Cox's proportional hazards analyses of the relationship between the use of hormone replacement therapy (HRT), obesity (waist circumference) and tumour‐cell specific HMG‐CoAR expression. We found that HMG‐CoAR was present in various fractions and intensities in the cytoplasm, sometimes with a membranous pattern, but not in the tumour cell nuclei. The expression of HMG‐CoAR was associated with a smaller tumour size (p = 0.02), low histological grade (p = 0.001), low Ki67 index (p = 0.004), ERα+ (p = 0.02), ERβ+ (p = 0.005), and high p27 expression (p = 50%) fraction of positive cells (relative risk: 2.06; 95% confidence interval: 1.20–3.51), and a strong staining intensity (2.33: 1.08–5.02). In summary, we demonstrate that HMG‐CoAR is differentially expressed in breast cancer and that a high expression is associated with prognostically favourable tumour parameters. Moreover, estrogen related life‐style and anthropometric factors might indeed regulate HMG‐CoAR expression.Keywords
This publication has 29 references indexed in Scilit:
- Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesisBlood, 2007
- Statin Use and Breast Cancer Risk in a Large Population-Based SettingCancer Epidemiology, Biomarkers & Prevention, 2007
- Molecular pathology of breast apocrine carcinomas: A protein expression signature specific for benign apocrine metaplasiaFEBS Letters, 2006
- Estrogenic regulation of cholesterol biosynthesis and cell growth in DLD-1 human colon cancer cellsScandinavian Journal of Gastroenterology, 2005
- The Risk of Cancer in Users of StatinsJournal of Clinical Oncology, 2004
- Breast cancer and hormone-replacement therapy: the Million Women StudyThe Lancet, 2003
- Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase InhibitorsClinical Pharmacokinetics, 1997
- Independent Behavior of Rat Liver LDL Receptor and HMGCoA Reductase under Estrogen TreatmentBiochemical and Biophysical Research Communications, 1996
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991
- Regulation of the mevalonate pathwayNature, 1990